We are pleased to announce the publication of our book chapter ‘New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development’ in ‘New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder’ Stanford SC, Scriberras E (Eds). Current Topics in Behavioral Neurosciences, 2022; 57: 79-126. Springer.
In the chapter we review the current status of drugs to treat ADHD, the clinical and non-clinical pharmacology of approved drugs to treat the disorder and the advances in R&D in the search for new drugs to treat ADHD. Our overview confirms the hypothesis that clinically effective ADHD drugs indirectly or directly increase catecholaminergic neurotransmission in the prefrontal cortex. New drugs approved for ADHD are catecholaminergic reuptake inhibitors and releasing agents or selective noradrenaline reuptake inhibitors. The focus continues to be on developing catecholaminergic and noradrenergic drugs and there is a dearth of drug-candidates with novel mechanisms entering development. However, considerable progress in ADHD pharmacotherapy has been achieved by once-daily medications with an extended duration of action and prodrugs which improve compliance, deliver greater efficacy and reduce risks for diversion and abuse.